Treatment of acute otitis media (AOM). AAP, AAFP, CDC, and others recommend amoxicillin as drug of first choice for initial treatment of AOM, unless patient has severe illness (moderate to severe otalgia or fever ≥39°C) or the infection is suspected of being caused by β-lactamase-producing Haemophilus influenzae or Moraxella catarrhalis, in which case the fixed combination of amoxicillin and clavulanate is recommended for initial treatment. Those who fail to respond to amoxicillin should be retreated with amoxicillin and clavulanate.
Has been used for prevention of recurrent AOM†. Such prophylaxisnot generally recommended since it is minimally effective and may promote emergence of resistance. Use only in selected patients with >3 episodes within 6 months or >4 episodes within 12 months; drugs of choice are amoxicillin or sulfisoxazole.
Has been used for management of otitis media with effusion† (OME). Anti-infectivesnot usually recommended; they provide only limited benefit in enhancing resolution of effusion and may promote resistance. AAP, AAFP, and others recommend watchful waiting for 3 months from date of effusion onset or diagnosis in those 2 months to 12 years of age who are not at risk for speech, language, or learning problems; some suggest a short course of anti-infectives may be considered for possible short-term benefits when parent and/or caregiver expresses a strong aversion to impending surgery. If anti-infectives are used, amoxicillin or the fixed combination of amoxicillin and clavulanate recommended.
Pharyngitis and Tonsillitis
Treatment of pharyngitis and tonsillitis caused by Streptococcus pyogenes (group A β-hemolytic streptococci).
AAP, IDSA, AHA, and others recommend oral penicillin V or IM penicillin G benzathine as treatments of choice; oral cephalosporins and oral macrolides are considered alternatives. Amoxicillin sometimes used instead of penicillin V, especially for young children.
A second episode can be retreated with the same or other treatment of choice; other regimens (amoxicillin and clavulanate, clindamycin, penicillin G benzathine with or without rifampin) recommended for symptomatic patients with multiple, recurrent episodes.
Consider that multiple, recurrent episodes of symptomatic pharyngitis within several months to years may indicate a streptococcal carrier experiencing repeated episodes of nonstreptococcal (e.g., viral) pharyngitis; treatment not usually recommended for streptococcal pharyngeal carriers.
Respiratory Tract Infections
Treatment of lower respiratory tract infections caused by susceptible Streptococcus (α- or β-hemolytic strains only), S. pneumoniae, Staphylococcus, or H. influenzae.
Skin and Skin Structure Infections
Treatment of skin and skin structure infections caused by susceptible Streptococcus (α- or β-hemolytic strains only), Staphylococcus, or Escherichia coli.
Urinary Tract Infections (UTIs)
Treatment of UTIs caused by susceptible Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. A drug of choice for treatment of uncomplicated UTIs caused by E. faecalis; consider high incidence of amoxicillin-resistant E. coli and other Enterobacteriaceae.
Gonorrhea
Previously used for treatment of acute uncomplicated gonorrhea (anogenital and urethral) caused by susceptible Neisseria gonorrhoeae. No longer recommended for gonorrhea by CDC or other experts (high incidence of penicillin-resistant strains).
Typhoid Fever and other Salmonella Infections
Alternative for treatment of typhoid fever† (enteric fever) caused by susceptible Salmonella typhi. Drugs of choice are fluoroquinolones and third generation cephalosporins (e.g., ceftriaxone, cefotaxime); consider that multidrug-resistant strains of S. typhi (strains resistant to ampicillin, amoxicillin, chloramphenicol, and/or co-trimoxazole) reported with increasing frequency.
Treatment of chronic carriers of S. typhi†; drugs of choice are fluoroquinolones (e.g., ciprofloxacin), ampicillin, or amoxicillin (with probenecid).
Alternative for treatment of gastroenteritis caused by nontyphoidal Salmonella†. Anti-infectives not indicated in otherwise healthy individuals with uncomplicated (noninvasive) gastroenteritis, but recommended if gastroenteritis is severe and in those at increased risk of invasive disease (e.g., <6 months or >50 years of age; hemoglobinopathies, severe atherosclerosis, valvular heart disease, prostheses, uremia, chronic GI disease, severe colitis; immunocompromised because of malignancy, immunosuppressive therapy, HIV infection). Drugs of choice are fluoroquinolones, third generation cephalosporins (cefotaxime, ceftriaxone), ampicillin, amoxicillin, co-trimoxazole, or chloramphenicol, depending on in vitro susceptibility.
Helicobacter pylori Infection and Duodenal Ulcer Disease
Treatment of Helicobacter pylori infection and duodenal ulcer disease (active or 1-year history of duodenal ulcer); eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
Used in a multidrug regimen that includes amoxicillin, clarithromycin, and either lansoprazole or omeprazole (triple therapy). Used with lansoprazole (dual therapy) in those allergic to or intolerant of clarithromycin or when clarithromycin resistance is suspected.
Lyme Disease
Treatment of early localized or early disseminated Lyme disease† associated with erythema migrans, in the absence of neurologic involvement or third-degree AV heart block.
IDSA, AAP, and others consider amoxicillin a drug of choice for treatment of early localized or early disseminated Lyme disease when oral therapy is appropriate. May be used in those with mild Lyme carditis, Lyme arthritis (without associated neurologic disease), or isolated facial nerve palsy (without other neurologic involvement).
Amoxicillin is the preferred oral agent for treatment in pregnant women and children <8 years of age who should not receive doxycycline.
Chlamydial Infections
Treatment of uncomplicated urethritis and cervicitis caused by Chlamydia trachomatis in pregnant women†. CDC and others recommend amoxicillin or a macrolide (azithromycin, erythromycin) as drugs of choice for treatment of urogenital chlamydial infections in these women.
Prevention of Bacterial Endocarditis
Prevention of bacterial endocarditis in patients undergoing certain dental, oral, respiratory tract, or esophageal procedures† who have cardiac conditions that put them at high or moderate risk. AHA recommends amoxicillin as drug of choice for such prophylaxis.
Prevention of bacterial endocarditis in patients undergoing certain GU and GI (except esophageal) procedures† who have cardiac conditions that put them at moderate-risk.
An alternative for follow-up to an initial parenteral regimen for prevention of bacterial endocarditis in patients undergoing certain GU and GI (except esophageal procedures† who have cardiac conditions that put them at high-risk.
Consult most recent AHA recommendations for specific information on which cardiac conditions are associated with high or moderate risk of endocarditis and which procedures require prophylaxis.
Prevention of S. pneumoniae Infections in Asplenic Individuals
Prevention of S. pneumoniae infections in children with anatomic or functional asplenia† (e.g., congenital, resulting from sickle cell disease or surgery) or children with malignant neoplasms or thalassemia.
Oral penicillin V usually drug of choice; some experts recommend amoxicillin.
Children at increased risk for pneumococcal infections should receive pneumococcal 7-valent conjugate vaccine and pneumococcal 23-valent polysaccharide vaccine. Long-term anti-infective prophylaxis recommended for children with functional or anatomic asplenia regardless of vaccination status.
Anthrax
An alternative for postexposure prophylaxis of anthrax† following exposure to aerosolized Bacillus anthracis spores (inhalational anthrax). Ciprofloxacin or doxycycline are initial drugs of choice for postexposure prophylaxis following a suspected or confirmed bioterrorism-related anthrax exposure. If penicillin susceptibility is confirmed, consideration can be given to changing prophylaxis to a penicillin in infants and children and in pregnant or lactating women; amoxicillin usually recommended.
An alternative for treatment of inhalational anthrax† when a parenteral regimen is not available (e.g., when there are supply or logistic problems in a mass-casualty setting).
An alternative for treatment of cutaneous anthrax†. If cutaneous anthrax occurs in the context of biologic warfare or bioterrorism, initial drugs of choice are ciprofloxacin or doxycycline. If penicillin susceptibility is confirmed, consideration can be given to changing to a penicillin in infants and children or in pregnant or lactating women; amoxicillin usually is recommended.
Dosage and Administration
Administration
Oral Administration
Administer orally without regard to meals.
Following reconstitution, the required amount of oral suspension should be placed directly on the child’s tongue for swallowing. Alternatively, the required amount of suspension can be added to infant formula, milk, fruit juice, water, ginger ale, or cold drinks and these fluids taken immediately and completely consumed.
For most infections, continue therapy for at least 48–72 hours after patient becomes asymptomatic or evidence that the infection is eradicated is obtained. The drug should be given for at least 10 days for treatment of infections caused by S. pyogenes (group A β-hemolytic streptococci).
Reconstitution
Reconstitute oral suspension at the time of dispensing. Tap bottle to thoroughly loosen powder and then add the amount of water specified on the bottle in 2 portions; agitate vigorously after each addition.
Agitate suspension well prior to administration of each dose.
Dosage
Available as the trihydrate; dosage expressed in terms of anhydrous amoxicillin.
Pediatric Patients
Neonates and infants ≤12 weeks (3 months) of age can receive amoxicillin in a dosage up to 30 mg/kg daily given in divided doses every 12 hours.
Pediatric dosage specified below is for those >3 months of age weighing <40 kg.
Children weighing ≥40 kg should receive usual adult dosage.
Otitis Media
Treatment of Acute Otitis Media (AOM)
Oral
80–90 mg/kg daily given in 2 or 3 divided doses† recommended by AAP, AAFP, CDC, and others.
Usual duration is 10 days; optimal duration is uncertain. AAP and AAFP recommend 10 days in those <6 years of age and in those with severe disease and state 5–7 days may be appropriate in those ≥6 years of age with mild to moderate AOM.
Prevention of Recurrent AOM
Oral
20 mg/kg daily given in 1 or 2 divided doses has been used.†
Pharyngitis and Tonsillitis
Oral
45 mg/kg daily in 2 divided doses or 40 mg/kg daily in 3 divided doses for 10 days.
50 mg/kg once daily or 750 mg once daily for 10 days†.
Follow-up throat cultures after treatment of pharyngitis and tonsillitis not indicated in asymptomatic patients, but recommended 2–7 days after treatment in those who remain symptomatic, develop recurring symptoms, or have a history of rheumatic fever and are at unusually high risk for recurrence.
Ear, Nose, and Throat Infections
Oral
25 mg/kg daily in divided doses every 12 hours or 20 mg/kg daily in divided doses every 8 hours for mild to moderate infections per manufacturer.
45 mg/kg daily in divided doses every 12 hours or 40 mg/kg in divided doses every 8 hours for severe infections per manufacturer.
Respiratory Tract Infections
Oral
45 mg/kg daily in divided doses every 12 hours or 40 mg/kg daily in divided doses every 8 hours for mild, moderate, or severe lower respiratory tract infections.
Skin and Skin Structure Infections
Oral
25 mg/kg daily in divided doses every 12 hours or 20 mg/kg daily in divided doses every 8 hours for mild to moderate infections.
45 mg/kg daily in divided doses every 12 hours or 40 mg/kg daily in divided doses every 8 hours for severe infections or those caused by less susceptible bacteria.
Urinary Tract Infections (UTIs)
Oral
25 mg/kg daily in divided doses every 12 hours or 20 mg/kg daily in divided doses every 8 hours for mild to moderate infections.
45 mg/kg daily in divided doses every 12 hours or 40 mg/kg daily in divided doses every 8 hours for severe infections or those caused by less susceptible bacteria.
Gonorrhea
Oral
Prepubertal children ≥2 years of age: 50 mg/kg as a single dose given with a single dose of probenecid (25 mg/kg).
No longer recommended for gonorrhea by the CDC or other experts.
Lyme Disease
Oral
25–50 mg/kg daily (up to 2 g daily) in 2–3 divided doses for 14–21 days for treatment of early localized or early disseminated Lyme disease†.
50 mg/kg daily in 3 divided doses for 14–28 days for mild Lyme carditis or for 28 days for Lyme arthritis (without associated neurologic disease).
Prevention of Bacterial Endocarditis
Patients Undergoing Certain Dental, Oral, Respiratory Tract, or Esophageal Procedures
Oral
50 mg/kg given 1 hour prior to the procedure.
Patients Undergoing Certain GU or GI (except Esophageal) Procedures
Oral
50 mg/kg as a single dose given 1 hour prior to the procedure for moderate-risk patients.
For high-risk patients, give an initial IM or IV dose of ampicillin with IM or IV gentamicin within 30 minutes of starting the procedure followed by 25 mg/kg of amoxicillin 6 hours later.
Prevention of S. pneumoniae Infections in Asplenic Individuals
Oral
20 mg/kg daily in children with anatomic or functional asplenia.†
In infants with sickle cell anemia, initiate prophylaxis as soon as diagnosis is established (preferably by 2 months of age); continue until approximately 5 years of age. Appropriate duration in children with asplenia from other causes unknown; some experts recommend that asplenic children at high risk receive prophylaxis throughout childhood and into adulthood.†
Anthrax
Postexposure Prophylaxis
Oral
80 mg/kg daily (maximum 1.5 g daily) given in divided doses every 8 hours for 60 days for postexposure prophylaxis following exposure to B. anthracis spores (inhalational anthrax)†.
500 mg every 8 hours for 60 days in those weighing ≥20 kg.
Use only if penicillin susceptibility is confirmed.
Inhalational Anthrax
Oral
80 mg/kg daily (maximum 1.5 g daily) given in divided doses every 8 hours for 60 days for treatment of inhalational anthrax in a mass-casualty setting†.
500 mg every 8 hours for 60 days for those weighing ≥20 kg.
Cutaneous Anthrax
Oral
80 mg/kg daily (maximum 1.5 g daily) given in divided doses every 8 hours for treatment of uncomplicated cutaneous anthrax†.
Treat for 60 days if cutaneous anthrax occurred as the result of exposure to aerosolized anthrax spores; 7–10 days may be adequate if it occurred as the result of natural or endemic exposure to anthrax.
Adults
Pharyngitis and Tonsillitis
Oral
500 mg 3 times daily or 750 mg once daily† for 10 days.
Follow-up throat cultures after treatment of pharyngitis and tonsillitis not indicated in asymptomatic patients, but recommended 2–7 days after treatment in those who remain symptomatic, develop recurring symptoms, or have a history of rheumatic fever and are at unusually high risk for recurrence.
Ear, Nose, and Throat Infections
Oral
500 mg every 12 hours or 250 mg every 8 hours for mild to moderate infections per manufacturer.
875 mg every 12 hours or 500 mg every 8 hours for severe infections or those caused by less susceptible bacteria per manufacturer.
Respiratory Tract Infections
Oral
875 mg every 12 hours or 500 mg every 8 hours for mild, moderate, or severe lower respiratory tract infections.
Skin and Skin Structure Infections
Oral
500 mg every 12 hours or 250 mg every 8 hours for mild to moderate infections.
875 mg every 12 hours or 500 mg every 8 hours for severe infections or those caused by less susceptible bacteria.
Urinary Tract Infections (UTIs)
Oral
500 mg every 12 hours or 250 mg every 8 hours for mild to moderate infections.
875 mg every 12 hours or 500 mg every 8 hours for severe infections or those caused by less susceptible bacteria.
Gonorrhea
Oral
3 g as a single dose.
No longer recommended for gonorrhea by the CDC or other experts.
Typhoid Fever
Oral
100 mg/kg daily or 1–1.5 g every 6 hours for 14 days.
Helicobacter pylori Infection and Duodenal Ulcer Disease
1 g 3 times daily for 14 days given in conjunction with lansoprazole (dual therapy).
Lyme Disease
Oral
500 mg 3 times daily for 14–21 days for treatment of early localized or early disseminated Lyme disease†.
500 mg 3 times daily for 14–28 days for mild Lyme carditis or for 28 days for Lyme arthritis (without associated neurologic disease).
Chlamydial Infections
Oral
500 mg 3 times daily for 7 days for treatment of chlamydial infections in pregnant women†.
Repeat testing (preferably by culture) recommended 3 weeks after completion of treatment.
Prevention of Bacterial Endocarditis
Patients Undergoing Certain Dental, Oral, Respiratory Tract, or Esophageal Procedures
Oral
2 g given 1 hour prior to the procedure.
Patients Undergoing Certain GU or GI (except Esophageal) Procedures
Oral
2 g given 1 hour prior to the procedure in moderate-risk patients.
For high-risk patients, give an initial IM or IV dose of ampicillin with IM or IV gentamicin within 30 minutes of starting the procedure followed by 1 g of amoxicillin 6 hours later.
Anthrax
Postexposure Prophylaxis
Oral
500 mg every 8 hours for 60 days for postexposure prophylaxis following exposure to B. anthracis spores†; use only if penicillin susceptibility confirmed.
Inhalational Anthrax
Oral
500 mg every 8 hours for 60 days for treatment of inhalational anthrax†.
Cutaneous Anthrax
Oral
500 mg every 8 hours for treatment of inhalational anthrax†.
Treat for 60 days if cutaneous anthrax occurred as the result of exposure to aerosolized anthrax spores; 7–10 days may be adequate if it occurred as the result of natural or endemic exposure to anthrax.
Prescribing Limits
Pediatric Patients
Neonates and Infants ≤12 weeks (3 Months) of Age
Oral
Maximum 30 mg/kg daily in divided doses every 12 hours.
Prevention of Bacterial Endocarditis
Oral
Dosage should not exceed adult dosage for prevention of bacterial endocarditis.
Special Populations
Renal Impairment
Dosage adjustment necessary in severe renal impairment.
Do not use 875-mg tablets in those with severe renal impairment and GFR <30 mL/minute.
Dosage recommendations not available for pediatric patients with renal impairment.
Dosage for Adults with Renal Impairment
GFR (mL/min)
Daily Dosage
10–30
250 or 500 mg every 12 hours depending on infection severity
<10
250 or 500 mg every 24 hours depending on infection severity
Possible emergence and overgrowth of nonsusceptible bacteria or fungi. Discontinue and institute appropriate therapy if superinfection occurs.
Treatment with anti-infectives may permit overgrowth of clostridia. Consider Clostridium difficile-associated diarrhea and colitis (antibiotic-associated pseudomembranous colitis) if diarrhea develops and manage accordingly.
Some mild cases of C. difficile-associated diarrhea and colitis may respond to discontinuance alone. Manage moderate to severe cases with fluid, electrolyte, and protein supplementation; appropriate anti-infective therapy (e.g., oral metronidazole or vancomycin) recommended if colitis is severe.
Sensitivity Reactions
Hypersensitivity Reactions
Serious and occasionally fatal hypersensitivity reactions, including anaphylaxis, reported with penicillins.
Prior to initiation of therapy, make careful inquiry regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other drugs. Partial cross-allergenicity occurs among penicillins and other β-lactam antibiotics including cephalosporins and cephamycins.
If a severe hypersensitivity reaction occurs, discontinue immediately and institute appropriate therapy as indicated (e.g., epinephrine, corticosteroids, maintenance of an adequate airway and oxygen).
General Precautions
Selection and Use of Anti-infectives
To reduce development of drug-resistant bacteria and maintain effectiveness of amoxicillin and other antibacterials, use only for treatment or prevention of infections proven or strongly suspected to be caused by susceptible bacteria.
When selecting or modifying anti-infective therapy, use results of culture and in vitro susceptibility testing. In the absence of such data, consider local epidemiology and susceptibility patterns when selecting anti-infectives for empiric therapy.
Hepatic Effects
Moderate increases in serum AST and/or ALT reported.
Hepatic dysfunction, including cholestatic jaundice, hepatic cholestasis, and acute cytolytic hepatitis reported.
Assess hepatic function periodically during prolonged therapy.
Renal Effects
Assess renal function periodically during prolonged therapy.
Assess hematologic function periodically during prolonged therapy.
Mononucleosis
Possible increased risk of rash in patients with mononucleosis; use in these patients not recommended.
Phenylketonuria
200- and 400-mg chewable tablets contain aspartame (NutraSweet®), which is metabolized in the GI tract to provide 1.82 or 3.64 mg of phenylalanine, respectively.
Oral suspensions do not contain aspartame and can be used in individuals with phenylketonuria (i.e., homozygous genetic deficiency of phenylalanine hydroxylase) and other individuals who must restrict their intake of phenylalanine.
Use of Fixed Combination
When used in fixed combination with other agents, consider the cautions, precautions, and contraindications associated with the concomitant agents.
Specific Populations
Pregnancy
Category B.
Recommended as an alternative for various indications in pregnant women (e.g., treatment of chlamydial infections†, treatment of Lyme disease†, postexposure prophylaxis or treatment of anthrax†).
Lactation
Distributed into milk; use with caution.
Use in a breast-feeding woman may result in sensitization of infants.
Recommended as an alternative for postexposure prophylaxis or treatment of anthrax† in women who are breast-feeding.
Pediatric Use
Renal clearance of amoxicillin may be delayed in neonates and young infants because of incompletely developed renal function.
Neonates and infants ≤12 weeks (3 months) of age should receive no more than 30 mg/kg daily given in divided doses every 12 hours.
Tooth discoloration (brown, yellow, gray) reported rarely, most frequently in pediatric patients. Brushing or dental cleaning reduces or eliminates discoloration in most cases.
Geriatric Use
Renal clearance may be decreased.
Hepatic Impairment
Assess hepatic function periodically during prolonged therapy.
Renal Impairment
Assess renal function periodically during prolonged therapy.
Dosage adjustments necessary in severe renal impairment.
In vitro and in vivo synergistic bactericidal effect
Used to therapeutic advantage in infections caused by β-lactamase-producing bacteria; commercially available in fixed combination with clavulanate potassium
Possible false-positive reactions in urine glucose tests using Clinitest®, Benedict’s solution, or Fehling’s solution; reported with ampicillin but no data regarding amoxicillin
Use glucose tests based on enzymatic glucose oxidase reactions (e.g., Clinistix®, Tes-Tape®)
Peak serum concentrations usually attained within 1–2 hours.
A 400-mg chewable tablet is bioequivalent to 5 mL of the oral suspension containing 400 mg/5 mL.
Food
Food has minimal or no effect on bioavailability of oral amoxicillin.
Special Populations
Oral absorption delayed in neonates compared with older children and adults; peak concentrations attained within 3–4.5 hours in neonates.
Distribution
Extent
Readily distributed into most tissues and fluids following oral administration, including lungs, bronchial secretions, maxillary sinus secretions, bile, pleural fluid, sputum, and middle ear fluid.
Only low concentrations attained in CSF.
Crosses the placenta and is distributed into human milk.
Plasma Protein Binding
17–20%.
Elimination
Metabolism
Probably metabolized to some extent in the liver.
Elimination Route
Eliminated principally in urine by both glomerular filtration and tubular secretion.
Approximately 50–80% of amoxicillin dose excreted unchanged in urine.
Half-life
1–1.4 hours.
Special Populations
Serum concentrations increased and half-life prolonged in patients with renal impairment.
Renal clearance may be delayed in neonates and young infants because of incompletely developed renal function.
Stability
Storage
Oral
Capsules
≤20°C.
For Suspension
250 mg/5 mL: ≤20°C. Following reconstitution, refrigerate (preferable but not required) and discard after 14 days.
200 or 400 mg/5 mL: ≤25°C. Following reconstitution, refrigerate (preferable but not required) and discard after 14 days.
Tablets
200- and 400-mg chewable tablets and 500- or 875-mg film-coated tablets: ≤25°C.
Actions
A β-lactam antibacterial classified as an aminopenicillin. The p-hydroxyl analog of ampicillin.
Usually bactericidal.
Gram-positive aerobes: Active in vitro and in clinical infections against Staphylococcus (β-lactamase-negative strains only), Streptococcus pneumoniae, other Streptococcus (α- and β-hemolytic strains only), and Enterococcus faecalis.
Gram-negative aerobes: Active in vitro and in clinical infections against H. influenzae, N. gonorrhoeae, E. coli, Corynebacterium diphtheriae, Listeria monocytogenes, Proteus mirabilis, Salmonella, and Shigella.
Other organisms: Active in vitro and in clinical infections caused by H. pylori. Also active against Borrelia burgdorferi.
Generally has same spectrum and level of activity as ampicillin, but more active than ampicillin against enterococci and Salmonella and less active against Shigella and Enterobacter.
Resistance reported in gram-positive and gram-negative bacteria that produce β-lactamases, including β-lactamase-producing S. aureus and E. faecalis.
Complete cross-resistance generally occurs between amoxicillin and ampicillin.
Importance of completing the entire prescribed course of treatment, even if feeling better after a few days.
Advise patients that skipping doses or not completing the full course of therapy may decrease effectiveness and increase the likelihood that bacteria will develop resistance and will not be treatable with amoxicillin or other antibacterials in the future.
Advise individuals with phenylketonuria and other individuals who must restrict their intake of phenylalanine that 200- and 400-mg chewable tablets contain aspartame (NutraSweet®), which is metabolized in the GI tract to phenylalanine.
Importance of discontinuing therapy and informing clinician if an allergic reaction occurs.
Importance of informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs.
Importance of women informing clinicians if they are or plan to become pregnant or to breast-feed.
Importance of advising patients of other important precautionary information. (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Amoxicillin (Trihydrate)
Routes
Dosage Forms
Strengths
Brand Names
Manufacturer
Oral
Capsules
250 mg (of amoxicillin)*
Trimox®
Sandoz
500 mg (of amoxicillin)*
Amoxil®
GlaxoSmithKline
Trimox®
Sandoz
For suspension
125 mg (of amoxicillin) per 5 mL*
Trimox®
Sandoz
200 mg (of amoxicillin) per 5 mL*
Amoxil®
GlaxoSmithKline
250 mg (of amoxicillin) per 5 mL*
Amoxil®
GlaxoSmithKline
Trimox®
Sandoz
50 mg (of amoxicillin) per mL
Amoxil® Pediatric Drops
GlaxoSmithKline
Trimox® Pediatric Drops
Sandoz
400 mg (of amoxicillin) per 5 mL*
Amoxil®
GlaxoSmithKline
Tablets, chewable
125 mg (of amoxicillin)*
Amoxicillin Chewable Tablets
Teva
Amoxil®
GlaxoSmithKline
200 mg (of amoxicillin)
Amoxil® (with aspartame)
GlaxoSmithKline
250 mg (of amoxicillin)*
Amoxil® (scored)
GlaxoSmithKline
400 mg (of amoxicillin)
Amoxil® (with aspartame)
GlaxoSmithKline
Tablets, film-coated
500 mg (of amoxicillin)*
Amoxicillin Tablets
Teva
Amoxil®
GlaxoSmithKline
875 mg (of amoxicillin)*
Amoxicillin Tablets (scored)
Teva
Amoxil® (scored)
GlaxoSmithKline
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 09/2009. For the most current and up-to-date pricing information, please visit www.drugstore.com. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
Remember, keep this and all other medicines out of the reach of children,
never share your medicines with others, and use this medication only for the indication prescribed.
Sign up with Facebook
